re: Ann: CAVATAK anti-cancer activity - US Ca...
Just clarifying a couple of aspects....
1. VLA will not be funding a Ph 3 trial.... ever. The cost runs into significant $millions.... hence the need for a Pharmaceutical Company with the resources to take over.
2. If we shareholders have to wait for all tests to be completed and then go into production.... before a takeover eventuates.... we may never see a decent reward.
3. The journey for minnow biotechs is always the same.... Trials.... good clinical data from the Trials.... catch the eye of interested Pharmas.... get taken over.
That's the normal course of events.
Good clinical data sends the share price up along the way.... then we have a choice to either take profits or ride it out.... time then tells if those who took profits laugh all the way to the bank, or weep at the forgone profits that would eventuate with a T/O offer.
Amgen/Biovex deal took place when good clinical data resulted during their Ph 2. trial. Biovex didn't have to wait until they went into production.
VLA Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
